stockrowBioAtla, Inc.
BCAB Healthcare Biotechnology
BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024.
- Revenue
- +4,233.3%
- EPS
- +101.7%
- Free cash flow
- +97.0%
Quarter to June 2026, against a year earlier
Follow BCAB
Alert me
BioAtla, Inc. (BCAB) EV/Sales
As of 6 November 2026, BioAtla, Inc. (BCAB) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −220× (May 2022) to 3,913× (April 2021); the current reading is higher than 37% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.2× | — |
| FY2024 | −0.9× | — |
| FY2021 | 752× | 451.76% |
| FY2020 | 136× | (85.99%) |
| FY2019 | 973× | 0.00% |
| FY2018 | 973× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | (74.07%) |
| Sep 2024 | 3.4× | (99.84%) |
| Jun 2021 | 2,085× | 1,429.32% |
| Dec 2020 | 136× | (85.99%) |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. compare | −19.2× |
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. | 0.7× |
| KALA KALA BIO, Inc. compare | 8.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 8.7× |
| ERNA Ernexa Therapeutics Inc. compare | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)